Literature DB >> 31343460

Combination of a δ-opioid Receptor Agonist and Loperamide Produces Peripherally-mediated Analgesic Synergy in Mice.

Daniel J Bruce1, Cristina D Peterson, Kelley F Kitto, Eyup Akgün, Sophia Lazzaroni, Phillip S Portoghese, Carolyn A Fairbanks, George L Wilcox.   

Abstract

BACKGROUND: The long-term use of opioids for analgesia carries significant risk for tolerance, addiction, and diversion. These adverse effects are largely mediated by μ-opioid receptors in the central nervous system. Based on the authors' previous observation that morphine and δ-opioid receptor agonists synergize in spinal cord in a protein kinase Cε-dependent manner, they predicted that this μ-opioid receptor-δ-opioid receptor synergy would take place in the central terminals of nociceptive afferent fibers and generalize to their peripheral terminals. Therefore, the authors hypothesized that loperamide, a highly efficacious μ-opioid receptor agonist that is excluded from the central nervous system, and oxymorphindole, a δ-opioid receptor agonist that was shown to synergize with morphine spinally, would synergistically reverse complete Freund's adjuvant-induced hyperalgesia.
METHODS: Using the Hargreaves assay for thermal nociception, the von Frey assay for mechanical nociception and the complete Freund's adjuvant-induced model of inflammatory pain, we tested the antinociceptive and antihyperalgesic effect of loperamide, oxymorphindole, or the loperamide-oxymorphindole combination. Animals (Institute for Cancer Research [ICR] CD1 strain mice; n = 511) received drug by systemic injection, intraplantar injection to the injured paw, or a transdermal solution on the injured paw. Dose-response curves for each route of administration and each nociceptive test were generated, and analgesic synergy was assessed by isobolographic analysis.
RESULTS: In naïve animals, the loperamide-oxymorphindole combination ED50 value was 10 times lower than the theoretical additive ED50 value whether given systemically or locally. In inflamed animals, the combination was 150 times more potent systemically, and 84 times more potent locally. All combinations showed statistically significant synergy when compared to the theoretical additive values, as verified by isobolographic analysis. The antihyperalgesia was ablated by a peripherally-restricted opioid antagonist.
CONCLUSIONS: From these data we conclude that the loperamide-oxymorphindole combination synergistically reverses complete Freund's adjuvant-induced inflammatory hyperalgesia. The authors also conclude that this interaction is mediated by opioid receptors located in the peripheral nervous system.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31343460      PMCID: PMC6693899          DOI: 10.1097/ALN.0000000000002840

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  48 in total

Review 1.  Opioids and sensory nerves.

Authors:  Christoph Stein; Christian Zöllner
Journal:  Handb Exp Pharmacol       Date:  2009

2.  Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists.

Authors:  P S Portoghese; M Sultana; H Nagase; A E Takemori
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

3.  A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.

Authors:  K Hargreaves; R Dubner; F Brown; C Flores; J Joris
Journal:  Pain       Date:  1988-01       Impact factor: 6.961

4.  Morphine directly inhibits nociceptors in inflamed skin.

Authors:  Heather N Wenk; Jill-Desiree Brederson; Christopher N Honda
Journal:  J Neurophysiol       Date:  2005-12-07       Impact factor: 2.714

5.  Antipruritic and antihyperalgesic actions of loperamide and analogs.

Authors:  Diane L DeHaven-Hudkins; Alan Cowan; Luz Cortes Burgos; Jeffrey D Daubert; Joel A Cassel; Robert N DeHaven; George B Kehner; Virendra Kumar
Journal:  Life Sci       Date:  2002-10-25       Impact factor: 5.037

6.  In vivo optogenetic activation of Nav1.8+ cutaneous nociceptors and their responses to natural stimuli.

Authors:  Megan L Uhelski; Daniel J Bruce; Philippe Séguéla; George L Wilcox; Donald A Simone
Journal:  J Neurophysiol       Date:  2017-03-15       Impact factor: 2.714

7.  Modulation of gastrointestinal function by MuDelta, a mixed µ opioid receptor agonist/ µ opioid receptor antagonist.

Authors:  P R Wade; J M Palmer; S McKenney; V Kenigs; K Chevalier; B A Moore; J R Mabus; P R Saunders; N H Wallace; C R Schneider; E S Kimball; H J Breslin; W He; P J Hornby
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

8.  Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons.

Authors:  C Zollner; M A Shaqura; C P Bopaiah; S Mousa; C Stein; M Schafer
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

9.  Non-invasive diagnosis of early pulmonary disease in PECAM-deficient mice using infrared pulse oximetry.

Authors:  Merideth A Early; Marta Lishnevsky; John M Gilchrist; David M Higgins; Ian M Orme; William A Muller; Mercedes Gonzalez-Juarerro; Alan R Schenkel
Journal:  Exp Mol Pathol       Date:  2009-07-28       Impact factor: 3.362

10.  Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist--loperamide.

Authors:  N Nozaki-Taguchi; T L Yaksh
Journal:  Anesthesiology       Date:  1999-01       Impact factor: 7.892

View more
  8 in total

1.  Convergent, functionally independent signaling by mu and delta opioid receptors in hippocampal parvalbumin interneurons.

Authors:  Xinyi Jenny He; Janki Patel; Connor E Weiss; Xiang Ma; Brenda L Bloodgood; Matthew R Banghart
Journal:  Elife       Date:  2021-11-17       Impact factor: 8.140

2.  Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity.

Authors:  Jessica I Griffith; Minjee Kim; Daniel J Bruce; Cristina D Peterson; Kelley F Kitto; Afroz S Mohammad; Sneha Rathi; Carolyn A Fairbanks; George L Wilcox; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2021-10-18       Impact factor: 4.030

3.  Topical Application of Loperamide/Oxymorphindole, Mu and Delta Opioid Receptor Agonists, Reduces Sensitization of C-fiber Nociceptors that Possess NaV1.8.

Authors:  Megan L Uhelski; Daniel Bruce; Rebecca Speltz; George L Wilcox; Donald A Simone
Journal:  Neuroscience       Date:  2020-08-25       Impact factor: 3.590

4.  The bivalent ligand, MMG22, reduces neuropathic pain after nerve injury without the side effects of traditional opioids.

Authors:  Rebecca Speltz; Mary M Lunzer; Sarah S Shueb; Eyup Akgün; Rachelle Reed; Alex Kalyuzhny; Philip S Portoghese; Donald A Simone
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

Review 5.  Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain-Narrative Review.

Authors:  Magdalena Kocot-Kępska; Renata Zajączkowska; Joanna Mika; David J Kopsky; Jerzy Wordliczek; Jan Dobrogowski; Anna Przeklasa-Muszyńska
Journal:  Pharmaceutics       Date:  2021-03-26       Impact factor: 6.321

6.  Anatomical Analysis of Transient Potential Vanilloid Receptor 1 (Trpv1+) and Mu-Opioid Receptor (Oprm1+) Co-expression in Rat Dorsal Root Ganglion Neurons.

Authors:  Wenting Ma; Matthew R Sapio; Allison P Manalo; Dragan Maric; Mary Kate Dougherty; Taichi Goto; Andrew J Mannes; Michael J Iadarola
Journal:  Front Mol Neurosci       Date:  2022-07-07       Impact factor: 6.261

7.  Distribution of delta and mu opioid receptor mRNA in rodent dorsal root ganglia neurons.

Authors:  Béatrice Quirion; Claudie Beaulieu; Laurie Côté; Jean-Luc Parent; Louis Gendron
Journal:  Eur J Neurosci       Date:  2022-06-14       Impact factor: 3.698

Review 8.  On the Role of Peripheral Sensory and Gut Mu Opioid Receptors: Peripheral Analgesia and Tolerance.

Authors:  Susanna Fürst; Zoltán S Zádori; Ferenc Zádor; Kornél Király; Mihály Balogh; Szilvia B László; Barbara Hutka; Amir Mohammadzadeh; Chiara Calabrese; Anna Rita Galambos; Pál Riba; Patrizia Romualdi; Sándor Benyhe; Júlia Timár; Helmut Schmidhammer; Mariana Spetea; Mahmoud Al-Khrasani
Journal:  Molecules       Date:  2020-05-26       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.